text_1: MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.
text_2: However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers.